Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Lorusso

Showing results (181-190 of 280) with videos related to

Pageof 28
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 15, 2011
Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumorsPatricia M Lorusso, Antonio Jimeno, Grace Dy, et al.
Journal of Clinical Pharmacology|September 29, 2011
Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancerManish Gupta, Patricia M Lorusso, Bei Wang, et al.
Oncotarget|February 18, 2017
Analysis of variability in high throughput screening data: applications to melanoma cell lines and drug responsesKuan-Fu Ding, Darren Finlay, Hongwei Yin, et al.
Investigational New Drugs|January 26, 2008
Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumorsPatricia M LoRusso, Shirish M Gadgeel, Antoinette Wozniak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2007
A phase I safety and pharmacologic study of a twice weekly dosing regimen of the oral taxane BMS-275183Linda E Bröker, Stephan A Veltkamp, Elisabeth I Heath, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2019
Challenges with Novel Clinical Trial Designs: Master ProtocolsMichael Cecchini, Eric H Rubin, Gideon M Blumenthal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2020
A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or LymphomaMonica M Mita, Patricia M LoRusso, Kyriakos P Papadopoulos, et al.
Current Drug Metabolism|April 6, 2012
Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolismBen-Quan Shen, Daniela Bumbaca, Ola Saad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2011
Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein bindingRichard A Graham, Bert L Lum, Sravanthi Cheeti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2014
Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumorsKyriakos P Papadopoulos, Josep Tabernero, Ben Markman, et al.
Pageof 28

Showing results (181-190 of 280) with videos related to

Sort By:
Pageof 28
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 15, 2011
Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumorsPatricia M Lorusso, Antonio Jimeno, Grace Dy, et al.
Journal of Clinical Pharmacology|September 29, 2011
Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancerManish Gupta, Patricia M Lorusso, Bei Wang, et al.
Oncotarget|February 18, 2017
Analysis of variability in high throughput screening data: applications to melanoma cell lines and drug responsesKuan-Fu Ding, Darren Finlay, Hongwei Yin, et al.
Investigational New Drugs|January 26, 2008
Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumorsPatricia M LoRusso, Shirish M Gadgeel, Antoinette Wozniak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2007
A phase I safety and pharmacologic study of a twice weekly dosing regimen of the oral taxane BMS-275183Linda E Bröker, Stephan A Veltkamp, Elisabeth I Heath, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2019
Challenges with Novel Clinical Trial Designs: Master ProtocolsMichael Cecchini, Eric H Rubin, Gideon M Blumenthal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2020
A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or LymphomaMonica M Mita, Patricia M LoRusso, Kyriakos P Papadopoulos, et al.
Current Drug Metabolism|April 6, 2012
Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolismBen-Quan Shen, Daniela Bumbaca, Ola Saad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2011
Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein bindingRichard A Graham, Bert L Lum, Sravanthi Cheeti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2014
Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumorsKyriakos P Papadopoulos, Josep Tabernero, Ben Markman, et al.
Pageof 28